Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction
01:10am, Monday, 15'th Sep 2025
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional informatio
Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction
02:56pm, Wednesday, 27'th Aug 2025
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional informatio
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)
06:30pm, Monday, 14'th Jul 2025
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of B
NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass. , June
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
02:51pm, Monday, 02'nd Jun 2025
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
01:00pm, Monday, 02'nd Jun 2025
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
12:48pm, Monday, 02'nd Jun 2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciar
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi. Click here to l
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders
06:51am, Monday, 02'nd Jun 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Blueprint Medicines Corporation (NASDAQ: BPMC) to Sanofi is fair to Blueprint shareholder
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
06:50am, Monday, 02'nd Jun 2025
The deal announced Monday is Sanofi's third of the year so far.
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
01:22am, Monday, 02'nd Jun 2025
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
